Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Viktravi and LOXO-195 with Bayer.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.